The intensity of RARRES2 immunoreaction within LE was greater in the VD3-treated, PCOS, and PCOS-and-VD3-treated groups than in the control, and lower in the PCOS-and-VD3-treated rats than in the VD3-treated rats (Figure 6K, p < 0.05). This evidence concerns the gene RARRES2 and polycystic ovary syndrome.